ROBERT DUPREY: Open Payments
NPI 1225312168 · KIRKLAND, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$280 in 14 payments from 7 companies in 2025. Trend: 2023 $17 · 2024 $478 · 2025 $280
Food & beverage: $280
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $97 |
| ABBVIE INC. | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, ABILIFY MAINTENA, AUSTEDO XR, REXULTI, SPRAVATO, LYBALVI.
Industry payments across WA — which companies pay providers there.
